Safety profile of orlistat: results of a prescription-event monitoring study (Q33434964)

26 July 2017

Safety profile of orlistat: results of a prescription-event monitoring study (English)

1 reference

26 July 2017

Acharya NV

1

1 reference

26 July 2017

Wilton LV

series ordinal

2

1 reference

26 July 2017

Shakir SA

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

21 March 2006

1 reference

International Journal of Obesity

26 July 2017

1 reference

26 July 2017

30

1 reference

26 July 2017

1645-1652

1 reference

26 July 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ijo.0803323

26 July 2017

0 references

cites work

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

21 January 2018

Obesity and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Orlistat associated with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Weight management and current options in pharmacotherapy: orlistat and sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

Prescription-event monitoring and reporting of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

inferred from DOI database lookup

7 January 2021

based on heuristic

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803323

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.IJO.0803323

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference